Metformin (generic), Glucophage Newswire (Page 2)

Metformin (generic), Glucophage Newswire (Page 2)

Comprehensive Real-Time News Feed for Metformin (generic), Glucophage. (Page 2)

Results 21 - 40 of 849 in Metformin (generic), Glucophage

  1. Trial to 'prevent' diabetes startsRead the original story w/Photo

    Tuesday Apr 19 | BBC News

    Children who have a parent or sibling with type-1 diabetes will be invited for a blood test to see if they are at high risk of developing the disease. Metformin is already used to treat diabetes, but it is not clear if it might prevent it from developing in the first place.

    Comment?

  2. This Common Type 2 Diabetes Drug May Be Safer Than OthersRead the original story w/Photo

    Tuesday Apr 19 | Health.com

    Metformin, the most frequently prescribed standalone drug for type 2 diabetes, is better for the heart than its closest competitors, a large analysis suggests. Metformin reduced the risk of dying from heart attack and stroke by about 30 percent to 40 percent compared with other commonly used drugs called sulfonylureas, such as glibenclamide, glimepiride, glipizide, and tolbutamide, researchers report.

    Comment?

  3. Evidence supports metformin as first-line treatment for diabetesRead the original story w/Photo

    Tuesday Apr 19 | Medical News Today

    A systematic evidence review and meta-analysis supports current guidelines recommending metformin as first-line therapy for type 2 diabetes . The review is published in Annals of Internal Medicine .

    Comment?

  4. Metformin Safer for Heart Than Other Diabetes DrugsRead the original story w/Photo

    Tuesday Apr 19 | News Max

    Metformin, the most frequently prescribed standalone drug for type 2 diabetes, is better for the heart than its closest competitors, a large analysis suggests. Metformin reduced the risk of dying from heart attack and stroke by about 30 percent to 40 percent compared with other commonly used drugs called sulfonylureas, such as glibenclamide, glimepiride, glipizide and tolbutamide, researchers report.

    Comment?

  5. Scots scientists in diabetes treatment trialRead the original story

    Wednesday Apr 20 | Scotsman.com

    Scientists are hoping for a breakthrough in the prevention of type 1 diabetes with the launch of a new trial. Children in Scotland - the country with the third highest rate of type 1 diabetes in the world - will take part in the study that aims to develop a cheap treatment to prevent the disease.

    Comment?

  6. Pioneering study to test if Type 1 diabetes 'triggered by lifestyle'Read the original story w/Photo

    Wednesday Apr 20 | Sunday Herald

    The Dundee study will investigate whether the diabetes drug, metformin, can be used to prevent the onset of Type 1 diabetes among high-risk individuals A PIONEERING new study is set to test the theory that type 1 diabetes is triggered by lifestyle and environmental stresses by trialling whether an existing drug treatment can prevent the condition from ever developing among high-risk individuals. There are around 6,400 families in Scotland affected by type 1 diabetes.

    Comment?

  7. Metformin Safer for Heart Than Other Common Type 2 Diabetes DrugsRead the original story w/Photo

    Monday Apr 18 | MedlinePlus

    Metformin, the most frequently prescribed standalone drug for type 2 diabetes, is better for the heart than its closest competitors, a large analysis suggests. Metformin reduced the risk of dying from heart attack and stroke by about 30 percent to 40 percent compared with other commonly used drugs called sulfonylureas, such as glibenclamide, glimepiride, glipizide and tolbutamide, researchers report.

    Comment?

  8. Metformin Safer for Heart Than Other Common Type 2 Diabetes Drugs: StudyRead the original story w/Photo

    Monday Apr 18 | Health.com

    Metformin, the most frequently prescribed standalone drug for type 2 diabetes, is better for the heart than its closest competitors, a large analysis suggests. Metformin reduced the risk of dying from heart attack and stroke by about 30 percent to 40 percent compared with other commonly used drugs called sulfonylureas, such as glibenclamide, glimepiride, glipizide and tolbutamide, researchers report.

    Comment?

  9. Diabetes Drug, Metformin, Lowers Risk of Heart Disease Deaths Better...Read the original story

    Monday Apr 18 | Newswise

    A new analysis of 204 studies involving more than 1.4 million people suggests that metformin, the most frequently prescribed stand-alone drug for type 2 diabetes, reduces the relative risk of a patient dying from heart disease by about 30 to 40 percent compared to its closest competitor drug, sulfonylurea. The study, designed to assess the comparative - not absolute or individual - benefits and risks of more than a dozen FDA-approved drugs for lowering blood sugar in type 2 diabetes, is described in the April 19 issue of the Annals of Internal Medicine .

    Comment?

  10. Type 2 Diabetes Drug, Metformin, May Reduce Cancer Death Risk In Postmenopausal WomenRead the original story w/Photo

    Monday Apr 18 | Medical Daily

    A widely prescribed drug for type 2 diabetes may also reduce the risk of dying from cancer in older women. A drug commonly prescribed to type 2 diabetes patients may also be able to cut cancer death risk in postmenopausal women, according to new research published in the International Journal of Cancer .

    Comment?

  11. Metformin may reduce cancer mortality riskRead the original story w/Photo

    Monday Apr 18 | PhysOrg Weblog

    Metformin may reduce the risk of dying from some cancers for postmenopausal women with type 2 diabetes, according to a study published in the April 15 issue of the International Journal of Cancer . The study team reviewed data from 145,826 postmenopausal women between the ages of 50 and 79. The information was collected between 1993 and 1998 and came from the Women's Health Initiative study.

    Comment?

  12. Diabetes drug, metformin, lowers risk of heart disease deaths better than sulfonylureasRead the original story w/Photo

    Sunday Apr 17 | EurekAlert!

    A new analysis of 204 studies involving more than 1.4 million people suggests that metformin, the most frequently prescribed stand-alone drug for type 2 diabetes, reduces the relative risk of a patient dying from heart disease by about 30 to 40 percent compared to its closest competitor drug, sulfonylurea. The study, designed to assess the comparative -- not absolute or individual -- benefits and risks of more than a dozen FDA-approved drugs for lowering blood sugar in type 2 diabetes, is described in the April 19, 2016 issue of the Annals of Internal Medicine .

    Comment?

  13. ACP urges immediate global action to avert devastating effects of climate changeRead the original story w/Photo

    Sunday Apr 17 | EurekAlert!

    To book Dr. Riley for an interview, contact Sue Higgins at DS Simon Media. Climate change will have devastating consequences for public and individual health unless aggressive, global action is taken now to curb greenhouse gas emissions, the American College of Physicians says in a new policy paper published in Annals of Internal Medicine .

    Comment?

  14. Sugar shock: Insulin costs tripled in 10 years, study findsRead the original story

    Sunday Apr 10 | Holtville Tribune

    People with diabetes who rely on insulin have seen the cost of that drug triple in just a decade - even as doctors have prescribed higher doses to drive down their blood sugar levels. Meanwhile, the cost of other diabetes drugs has stayed about the same or even gone down.

    Comment?

  15. The impact of initial antidiabetic agent and use of monitoring agents ...Read the original story

    Sunday Apr 10 | CiteULike

    The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  16. A wearable graphene-based biomedical device to monitor and treat diabetesRead the original story w/Photo

    Mar 22, 2016 | KurzweilAI.net

    A wearable graphene-based patch that allows for accurate non-invasive blood-sugar diabetes monitoring and painless drug delivery has been developed by researchers at The Institute for Basic Science Center for Nanoparticle Research in South Korea. The device uses a hybrid of gold-doped graphene and a serpentine-shape gold mesh to measure pH and temperature by measuring the amount of glucose in sweat.

    Comment?

  17. FDA Warns of Heart Failure Risk With Diabetes Medications Containing Saxagliptin or AlogliptinRead the original story

    Friday Apr 8 | P&T Community

    An FDA safety review has found that type-2 diabetes medications containing saxagliptin or alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result, the agency has added new warnings and precautions Saxagliptin and alogliptin are part of the class of dipeptidyl peptidase-4 inhibitor drugs, which are used with diet and exercise to lower blood sugar in adults with type-2 diabetes.

    Comment?

  18. Adding Glucose-Lowering Agents Delays Insulin Initiation and Prolongs HyperglycemiaRead the original story

    Friday Apr 8 | The American Journal of Managed Care

    A review of national Veterans Health Administration data has identified how the number of glucose-lowering agents used prior to insulin initiation impacts glycemic control. Courtney Hugie, PharmD, BCPS; Nancee V. Waterbury, PharmD, BCACP; Bruce Alexander, PharmD; Robert F. Shaw, PharmD, MPH, BCPS, BCNSP; and Jason A. Egge, PharmD, MS, BCPS Nine classes of glucose-lowering agents are available for patients with type 2 diabetes prior to starting insulin.

    Comment?

  19. Post-menopausal Women Taking Metformin for Diabetes May be at Lower Risk of CancerRead the original story w/Photo

    Friday Apr 8 | Health News Digest

    Post-menopausal women who use metformin long-term for the treatment of diabetes may be at lower risk for developing certain cancers and dying from these diseases, reports a large prospective study from researchers at Roswell Park Cancer Institute and the University at Buffalo. Their analysis was based on data from the Women's Health Initiative , a series of large studies undertaken to address common health issues in wo - BUFFALO, N.Y. - Post-menopausal women who use metformin long-term for the men.

    Comment?

  20. The amazing technological game changer is hereRead the original story

    Friday Apr 8 | Balloon Juice

    Medicare recently authorized a creative new diabetes prevention benefit that leads to better health results and significantly lower costs. The core technological driver is talking and coaching at the YMCA.

    Comment?